Table 1.

Summary of EphA2 Expression Analyses in Human Solid Tumors

Cancer typePublicationsCell linesTissueNotes
BreastMacrae et al. (47)YNEphA2 is overexpressed in 8 of 28 breast cancer cell lines and is a direct transcriptional target of the Ras-Raf-MAPK pathway.
Zelinski et al. (75)YYEphA2 overexpression sufficient to transform mammary epithelial cells.
Fox and Kandpal (74)YNUp-regulation of ephA2 and down-regulation of ephrinA1 gene expression in more invasive and tumorigenic breast cancer cells.
OvaryThaker et al. (76)YY75.9% of tumors overexpressed EphA2. EphA2 overexpression was significantly associated with higher grade, advanced disease stage, and shorter survival.
Lin et al. (77)YYEphA2 overexpressed in 76% of tumors and associated with advanced-stage disease. EphA2 expressed in tumor and endothelial cells was associated with factors involved in invasion and angiogenesis.
ProstateWalker-Daniels et al. (78)YYEphA2 overexpressed more in metastatic cells than noninvasive epithelial cells.
Zeng et al. (79)NYEphA2 levels increase as prostatic epithelial cells move toward a more aggressive phenotype.
PancreasMudali et al. (80)YYEphA2 overexpressed in 95% of clinical specimens and associated with metastatic disease.
Duxbury et al. (56)YNEphA2 expression associated with increased cellular invasiveness.
GlioblastomaWykosky et al. (81)YYEphA2 is overexpressed but not tyrosine phosphorylated in GBM cells or tumors.
Wykosky et al. (82)YYEphA2 strongly overexpressed in 61% of GBM tumors and is significantly associated with astrocytoma grade.
Liu et al. (83)YYEphA2 expression is associated with poor patient survival.
Wang et al. (84)NYEphA2 strongly overexpressed in 60% of primary and recurrent GBM tumors. Increased expression significantly associated with adverse patient outcome.
RenalHerrem et al. (92)NYHigher levels of EphA2 correlated with tumors that were of higher grade, larger, and more highly vascularized. EphA2 was predictive of shorter survival.
LungKinch et al. (85)YYHigh levels of EphA2 predict shorter survival and brain metastases.
MelanomaHess et al. (86)YYEphA2 is expressed and phosphorylated specifically in aggressive metastatic melanoma cells and functions in vasculogenic mimicry.
BladderAbraham et al. (87)YYEphA2 staining intensity associated with advancing stages of urothelial carcinoma.
GastricNakamura et al. (88)YYAnalysis of EphA2 gene and protein expression. EphA2 expression highest in macroscopic type 3 and 4 tumors.
EsophagealMiyazaki et al. (89)YYEphA2 overexpressed in 50% of patient tumors and correlated with lymph node metastasis and poor survival rates.
ColorectalKataoka et al. (90)YYOverexpression of EphA2 more in early-stage tumors than late stage and more in smaller tumors than large tumors. Microvessel count correlated with overexpression of EphA2.
CervicalWu et al. (91)YYHigh level of EphA2 predictive of shorter overall survival.